Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (340)	12/17/2002 9:30:47 AM
From: tuck	Read Replies (1) \| Respond to of 887

>>SOUTH SAN FRANCISCO, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK - News) today announced that Fox Chase Cancer Center (Philadelphia, PA) has joined Telik's network of collaborators in cancer drug discovery. This network includes leading cancer research institutions working to apply Telik's proprietary drug discovery technology, TRAP, to new cancer targets, to identify novel pharmaceutically active compounds. "Telik's computational TRAP technology will enable our researchers to identify compounds with pharmacologic activity in a more focused and efficient manner than is possible with conventional screening methods that typically may involve testing thousands of compounds," said Louis M. Weiner, M.D., vice president of Translational Research and chairman of the Department of Molecular Oncology at Fox Chase Cancer Center. "It is a technology that is well-suited to assist in the translation of important advances in cancer biology occurring here at Fox Chase for the ultimate benefit of the cancer patient." Under its agreement with Telik, Fox Chase Cancer Center evaluates TRAP-identified compounds for pharmacologic activity against cancer-related drug targets. Telik has worldwide rights to develop and commercialize selected compounds resulting from the collaboration and will use Fox Chase as a preferred clinical site for its oncology drug development programs arising from this collaboration. "We are pleased to extend our TRAP collaborations to include the scientists at Fox Chase," said James G. Keck, Ph.D., Telik's vice president, biology research. "The results of these collaborations are an important source for our future cancer product pipeline as well as an important resource for expertise in both basic and clinical oncology." Telik's TRAP technology enables the ultra-efficient discovery of small molecule product candidates. TRAP takes advantage of the fundamental principle that pharmaceutically active molecules work by interacting with a protein target. Telik measures the binding of a small molecule to a proprietary reference panel of proteins to create a profile for each compound. Telik scientists have created a database of profiles for tens of thousands of compounds, and they use sophisticated computational tools to search the database and identify drug candidates more rapidly than with alternative technologies. Fox Chase is an independent, not for profit institution devoted to improving cancer treatment and prevention. Its mission is to reduce the burden of human cancer through the highest-quality programs in research and patient care, including cancer prevention, treatment, early detection and education. Fox Chase Cancer Center (www.fccc.edu) is a Comprehensive Cancer Center designated by the National Cancer Institute.<< snip Cheers, Tuck